Dr. Deborah A. Mosca has more than 40 years of experience as a proven leader of multi-disciplinary, inter-institutional project teams, guiding the discovery and development of novel therapeutic agents across various sectors, including biotech, non-profits, and large pharma. At XCMR, she will oversee life-science work in the research, development, and commercialization of electromagnetic devices to protect against infectious agents, such as SARS-CoV-2 and other pathogens.
Previously, Dr. Mosca served as chairman and CEO of the Marine Bio-Technologies Center of Innovation, where she developed a business strategy to commercialize marine biotechnologies. Before that, at PaxVax, she provided strategic leadership for vaccine development, contributing to revenue generation through partnerships, contracts, and licensing.
Dr. Mosca holds a BS in Biology and Genetics from Cornell University and a PhD in Biology from the State University of New York at Buffalo. She has published over 42 papers and abstracts and has been involved in the approval of seven patents.
“We are pleased to welcome Dr. Deborah Mosca to XCMR,” said Richard Rasansky, CEO of XCMR. “Her extensive experience in life-science research and her leadership in developing therapeutic innovations make her an invaluable asset to XCMR’s mission of combating infectious diseases.”
